Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Read more about Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium.
Integrative molecular profiling of routine clinical prostate cancer specimens. Read more about Integrative molecular profiling of routine clinical prostate cancer specimens.
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Read more about Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Read more about Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Read more about Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.
Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort. Read more about Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort.
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Read more about ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Read more about Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Read more about The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond. Read more about Reply to the letter to the editor 'Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer' Tannock and Pond.
